Treating hepatitis C in the prison population is cost‐saving

Jennifer A. Tan, Tom A. Joseph, Sammy Saab – 28 October 2008 – The prevalence of chronic hepatitis C infection in U.S. prisons is 12% to 31%. Treatment of this substantial portion of the population has been subject to much controversy, both medically and legally. Studies have demonstrated that treatment of chronic hepatitis C with pegylated interferon (PEG IFN) and ribavirin is a cost‐effective measure in the general population; however, no study has addressed whether the same is true of the prison population.

Fatty acid synthase is up‐regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production

Wei Yang, Brian L. Hood, Sara L. Chadwick, Shufeng Liu, Simon C. Watkins, Guangxiang Luo, Thomas P. Conrads, Tianyi Wang – 28 October 2008 – Hepatitis C virus (HCV) is a major human pathogen that causes serious illness, including acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II

Lin Wang, Huiping Dong, Carol J. Soroka, Ning Wei, James L. Boyer, Mark Hochstrasser – 28 October 2008 – The bile salt export pump (Bsep) represents the major bile salt transport system at the canalicular membrane of hepatocytes. When examined in model cell lines, genetic mutations in the BSEP gene impair its targeting and transport function, contributing to the pathogenesis of progressive familial intrahepatic cholestasis type II (PFIC II).

Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ribavirin for 48 weeks in chronic hepatitis C virus‐1 infection

Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser, Ulrich Spengler, Holger Hinrichsen, Hans Weidenbach, Guido Gerken, Michael Manns, Peter Buggisch, Eva Herrmann, Stefan Zeuzem – 28 October 2008 – The impact of amantadine on virologic response rates of interferon‐based treatment of chronic hepatitis C is controversial.

Impact of the hepatitis B virus genotype on pre– and post–liver transplantation outcomes

Paul Gaglio, Sundeep Singh, Bulent Degertekin, Michael Ishitani, Munira Hussain, Robert Perrillo, Anna S. Lok – 29 September 2008 – Emerging data suggest that the hepatitis B virus (HBV) genotype and the precore and core promoter variants impact the outcome of orthotopic liver transplantation (OLT) for hepatitis B. The aim of this study was to determine if there is a correlation between HBV genotype, precore and core promoter variants, and pre‐ and post‐OLT outcomes.

Temporary portocaval shunt in orthotopic liver transplantation: Need for a standardized approach?

Diego Davila, Adam Bartlett, Nigel Heaton – 29 September 2008 – Maintenance of portal and systemic venous return during the anhepatic phase of liver transplantation (LT) improves hemodynamic stability. With the piggyback technique, caval return is maintained; however, temporary clamping of the portal vein is still necessary. The use of a temporary portocaval shunt (TPCS) has been proposed to minimize the effect of portal venous interruption.

Subscribe to